Pfizer Inc. reported second-quarter 2026 revenues of $15.0 billion and an adjusted diluted EPS of $0.77, while reporting a GAAP loss per share of $(0.04) due to $4.3 billion in non-cash intangible asset impairments. The company raised its full-year 2026 revenue guidance midpoint by $500 million to $61.5 billion and reaffirmed adjusted diluted EPS guidance of $2.80 to $3.00. Pfizer announced an expansion of productivity enhancement initiatives, targeting an additional $2.5 billion in net cost savings from 2027 through 2029. CFO Dave Denton is stepping down on August 15, with Cecile Guegan named Interim CFO effective August 16. The company also completed a strategic licensing agreement with Innovent Biologics for $650 million upfront plus up to $9.85 billion in milestones. Pfizer operates in the global biopharmaceutical industry, developing and commercializing prescription medicines, vaccines, and consumer health products.

Pfizer Inc. reaffirmed its full-year 2026 guidance, projecting Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00. This reaffirmation follows the disclosure of the company's Chief Financial Officer transition. Pfizer Inc. is a biopharmaceutical company that develops, manufactures, and markets medicines and vaccines.

Chief Financial Officer Dave Denton will step down from Pfizer Inc. on August 15, 2026, to pursue a role in the consumer goods industry. The company stated his departure is unrelated to financial results or disagreements regarding accounting or reporting policies. Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer effective August 16, 2026, while a search for a permanent successor is conducted. Pfizer is a pharmaceutical company that develops and manufactures medicines.